CN102268031B - 合成埃坡霉素碳1-6片段的中间体、合成方法和用途 - Google Patents

合成埃坡霉素碳1-6片段的中间体、合成方法和用途 Download PDF

Info

Publication number
CN102268031B
CN102268031B CN201110158837.5A CN201110158837A CN102268031B CN 102268031 B CN102268031 B CN 102268031B CN 201110158837 A CN201110158837 A CN 201110158837A CN 102268031 B CN102268031 B CN 102268031B
Authority
CN
China
Prior art keywords
compound
esperamicin
carbon
synthetic
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201110158837.5A
Other languages
English (en)
Other versions
CN102268031A (zh
Inventor
林国强
孙炳峰
王杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Organic Chemistry of CAS
Original Assignee
Shanghai Institute of Organic Chemistry of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Organic Chemistry of CAS filed Critical Shanghai Institute of Organic Chemistry of CAS
Priority to CN201110158837.5A priority Critical patent/CN102268031B/zh
Publication of CN102268031A publication Critical patent/CN102268031A/zh
Application granted granted Critical
Publication of CN102268031B publication Critical patent/CN102268031B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

本发明属于药物合成技术领域,具体涉及一种合成埃坡霉素碳1-6片段的中间体、合成方法和用途,具有如下的结构式。

Description

合成埃坡霉素碳1-6片段的中间体、合成方法和用途
技术领域
本发明属于药物合成技术领域,具体涉及一种合成埃坡霉素碳1-6片段的中间体、合成方法以及用于合成埃坡霉素碳1-6片段的用途。
背景技术
埃坡霉素,英文名epothilone,为具有抗癌活性的大环内酯,研究表明其抗癌机制与紫杉醇类似,即抑制微管解聚从而抑制细胞分裂,但其结构比紫杉醇简单得多,且水溶性更好,易于成药,且对紫杉醇耐药瘤株有效。2007年10月美国FDA批准BMS公司研发的epothilone B的酰胺类似物伊莎贝隆(ixabepilone)用于其他化疗药物无效的晚期或转移性乳腺癌的治疗。
1-1埃坡霉素A,B(epothilone A,B),伊莎贝隆(ixabepilone)
由于埃坡霉素分子结构相对简单,有可能通过化学合成的手段大规模生产。国际和国内超过十个研究组进行了埃坡霉素的全合成研究,国外如美国Danishefsky研究组:Angew.Chem.Int.Ed.1996,35,2801-2803;J.Am.Chem.Soc.1997,119,2733-2734;J.Am.Chem.Soc.1997,119,10073-10092;美国Nicolaou研究组:Angew.Chem.Int.Ed.1996,35,2399-2401;Angew.Chem.Int.Ed.1997,36,166-168;Angew.Chem.Int.Ed.1997,36,525-527;J.Am.Chem.Soc.1997,119,7974-7991;国内刘志煜研究组:Chem.Eur.J.2002,8,3747-3756;CN99124010.3,异埃坡霉素、合成方法及用途;CN99124008.1,埃坡霉素中间体碳1-6片段化合物及其用途;CN 99124009.X,埃坡霉素中间体碳1-6片段的合成新方法。分析这些文献可知,在合成epothilone及其类似物时,碳1-6片段(1)是合成埃坡霉素的通用关键中间体。
碳1-6片段(1)含有一个手性二级羟基,一个偕二甲基取代的季碳中心,一个酮羰基,以及一个羧基,合成关键是高对映选择性地建立手性二级羟基。国内外已有几篇关于该C1-C6片段的合成专利,如CN1254708,CN1418881以及DE10051136,但是都存在不足之处。
发明内容
本发明要解决的问题是提供一种埃坡霉素碳1-6片段(1)的合成中间体;
本发明要解决的问题是提供一种上述埃坡霉素碳1-6片段(1)的合成中间体的合成方法;
本发明要解决的另外一个问题是提供一种上述埃坡霉素碳1-6片段(1)的合成中间体的用途。通用高效的埃坡霉素碳1-6片段(1)的新合成路线。本发明合成路线如反应式1-2所示。
Figure BDA0000068066050000021
本发明的埃坡霉素碳1-6片段(1)的合成中间体具有如下的结构式:
Figure BDA0000068066050000022
其中,R2=X(4)或R(5);R1为苄基Bn、对甲氧基苄基PMB、甲氧甲基MOM、三甲硅基TMS、叔丁基二甲基硅TBS、三乙基硅TES、乙酰基Ac、特戊酰基Piv或苯甲酰基Bz;所述的R为烷基,特别是乙基Et;所述的X为卤素Br、卤素I或三氟甲磺酸酯OTf。
本发明中间体的合成方法结合以上各步骤反应说明如下:
a.这步涉及将非手性底物2,2-二甲基-1,3-环戊二酮去对称化,生成手性醇(2),为已知化合物,文献US20040235958以及Journal of the American Chemical Society 2007,129,10346-10347.有合成方法。前者采用酶还原法,后者采用CBS催化还原,本发明采用后一种方法,即CBS,儿茶酚硼烷,优点是操作方便,适合大量制备。
b.将(2)中醇羟基进行保护,优先选择TBS保护基,优先选用反应试剂TBSCl/imidazole,也可用反应试剂TBSOTf/2,6-lutidine,但后者价格昂贵。所述的TBSCl表示叔丁基二甲基氯硅烷;所述的imidazole表示咪唑;所述的TBSOTf表示叔丁基二甲基硅醇三氟甲磺酸酯;所述的2,6-lutidine表示2,6-二甲基吡啶。
c.在有机溶剂中和强碱中,化合物(3)和三氟甲磺酰化试剂反应0.1~2小时得到相应三氟甲磺酸酯;所述的化合物(3)、三氟甲磺酰化试剂和强碱的摩尔比为1∶1~5∶1~5;所述的强碱是六甲基二硅氨基钾(KHMDS)、六甲基二硅氨基钠(NaHMDS)、六甲基二硅氨基锂(LiHMDS)、或二异丙基氨基锂(LDA);所述的三氟甲磺酰化试剂是三氟甲磺酸酐(Tf)2O、Hendrickson试剂[(Tf)2NPh]或Comins试剂[(Tf)2NPyCl]。
d.在有机溶剂中和催化剂存在下,化合物(4)与金属试剂R2-M进行偶联反应0.5~10小时得到(5),所述的化合物(4)与金属试剂R2-M的摩尔比为1∶1~3;所述的化合物(4)与催化剂的摩尔比为1∶0.001~0.2;所述的催化剂为以钯为催化中心的催化剂,例如但不限于Pd(PPh3)4、PdCl2(PPh3)4、Pd(PBu3)4或Buckwald系列催化剂。
e.此步反应为臭氧化断裂双键,可以在反应后用酸处理直接得到酸,也可以还原得到醛,再用亚氯酸钠氧化得到酸。其中,R2=X和R;R1为苄基Bn、对甲氧基苄基PMB、甲氧甲基MOM、三甲硅基TMS、叔丁基二甲基硅TBS、三乙基硅TES、乙酰基Ac、特戊酰基Piv或苯甲酰基Bz;所述的R为C1~6的烷基;所述的X为卤素Br、卤素I或三氟甲磺酸酯OTf;M为Zn、Mg、Li、Cu、Sn、B或Si。
本发明的用于合成埃坡霉素碳1-6片段的中间体、合成方法简便和可以用于合成埃坡霉素碳1-6片段(1)。
具体实施方式
实施例1(S)-3-羟基-2,2-二甲基环戊酮(2)的制备
50mL的蛋形瓶上接恒压滴液漏斗和回流冷凝管,滴液漏斗中加棉花和4A分子筛。加入丁基硼酸(143mg,1.4mmol,10%mmol)、二苯基脯氨醇(355mg,1.4mmol,10%mmol)和甲苯(35mL),加热回流3h,加入二甲基环戊二酮(1.76g,14mmol),加甲苯(28mL)溶解,加N,N-二乙基苯胺(1.13mL,7mmol),冷却至-60℃。Catecholborane(2.75mL,25.2mmol)溶于干燥的甲苯通过自动进样器沿瓶壁缓慢的加到体系中(进样持续2h)。加完后保持-60℃反应2-3小时。用乙醚稀释,加饱和NaHCO3,二氯甲烷萃取三次,干燥,浓缩,过硅胶柱得产物1.10g,产率61%。
手性GC测得ee值为95.9%。GC色谱柱型号:Rt-βDE Xcst,GC条件:50℃保持2min,以3℃/min的速度升至150℃保持5min,以5℃/min的速度升至180℃,柱压为10psi。
1H NMR(CDCl3,400MHz):δ4.05(m,1H),2.52-2.41(m,1H),2.31-2.20(m,2H),1.97-1.86(m,1H),1.04(s,6H)
13C NMR(CDCl3,100MHz):δ221.4,78.2,50.1,34.2,27.7,22.2,16.8
[α]D 24+13.7(c=1.2,CHCl3)。
实施例2(S)-3-(叔丁基二甲基硅氧基)-2,2-二甲基环戊酮(3a)的制备
化合物(2)(729mg,5.7mmol)加至瓶中,加DCM(4mL),加咪唑(1.163g,17.1mmol)搅拌至完全溶解后,加入TBSCl(1.716g,11.4mmol)。16小时后,加饱和NaHCO3淬灭,DCM萃取,干燥,浓缩,硅胶柱层析得目标产物(1.258g),产率91%。
1H NMR(CDCl3,400MHz)δ3.95(m,1H),2.49-2.38(m,1H),2.25-2.09(m,2H),1.88-1.78(m,1H),0.99(s,3H),0.97(s,3H),0.89(s,9H),0.08(s,3H),0.07(s,3H).
13C NMR(CDCl3,100MHz)δ221.4,78.6,50.3,34.2,28.4,25.7,22.1,17.5,-4.6,-5.0.
[α]D 25+28.0(c=0.9,CHCl3).
实施例3(S)-4-(叔丁基二甲基硅氧基)-5,5-二甲基环戊-1-烯基三氟甲磺酸酯(4a)的制备
化合物(3a)(1.13g,4.66mmol),加THF(32mL)冷却至-78℃,加六甲基二硅氨基钾(14.0mL,1M in THF),保持1小时,PhN(Tf)2(5.82g,16.3mmol)溶于THF(18mL)加至体系中,2小时候加饱和NaHCO3淬灭,升至室温后DCM萃取,干燥,浓缩过硅胶柱,得产物1.60g,产率91%。
1H NMR(CDCl3,400MHz):δ5.43(br dd,J1=3.0Hz,J2=2.0Hz,1H),4.00(dd,J1=7.3Hz,J2=6.8Hz,1H),2.53(ddd,J1=15.6Hz,J2=7.3Hz,J3=3.0Hz,1H),2.21(ddd,J1=15.6Hz,J2=6.8Hz,J3=2.0Hz,1H),1.08(s,3H),1.02(s,3H),0.90(s,9H),0.07(s,3H),0.06(s,3H).
13C NMR(CDCl3,100MHz)δ154.0,118.6(q,JC-F=320.3Hz),109.9,78.1,46.3,35.6,25.7,23.6,18.4,-4.6,-5.0.
[α]D 25+9.5(c=0.9,CHCl3)。
实施例4(S)-叔丁基(3-乙基-2,2-二甲基环戊-3-烯基氧)二甲基硅烷(5a)的制备
化合物(4a)(1.42g,3.78mmol)与Pd(PPh3)4(219mg,5%mol)加入250mL瓶中,加THF(75mL)搅拌并降至-78℃换气,加Et2Zn(7.56mL,1.0M in己烷(hexane))。室温反应1小时,加饱和NH4Cl(6mL)淬灭,分液分出上层液体,下层再用二氯甲烷萃取,干燥,浓缩,过硅胶柱得产物803mg,产率83%。
1H NMR(CDCl3,400MHz):δ5.14(m,1H),3.89(dd,J1=7.3Hz,J2=6.8Hz,1H),2.53(ddd,J1=15.6Hz,J2=7.3Hz,J3=3.0Hz,1H),2.21(ddd,J1=15.6Hz,J2=6.8Hz,J3=2.0Hz,1H),1.08(s,3H),1.02(s,3H),0.90(s,9H),0.07(s,3H),0.06(s,3H).
[α]D 25+4.1(c=0.9,CHCl3)。
实施例5(S)-3-(叔丁基二甲基硅氧基)-4,4-二甲基-5-氧代庚酸(1)的制备
化合物(5a)(736mg,2.89mmol)溶于DCM-MeOH(4∶1,75mL),冷却至-78℃,通O3至体系成蓝色并保持不褪色。加醋酸1mL并缓慢升至室温搅拌。浓缩过硅胶柱得产物(565mg),产率65%。所述的DCM是二氯甲烷。
1H NMR(CDCl3,400MHz):δ4.48(dd,J1=3.6Hz,J2=7.0Hz,1H),2.56-2.48(m,2H),2.37-2.31(m,1H),1.14(s,3H),1.09(s,3H),1.01(t,J=7.0Hz,3H),0.85(s,9H),0.06(s,3H),0.05(s,3H).
13C NMR(CDCl3,100MHz)δ215.3,177.7,73.5,52.4,39.1,31.8,25.8,20.8,20.4,18.0,7.5,-4.6,-5.0
[α]D 26-18.4(c=0.95,CHCl3)。

Claims (3)

1.一种合成埃坡霉素碳1—6片段1的中间体,所述的埃坡霉素碳1—6片段1的结构式如下:
Figure FDA0000458287090000011
其特征是所述的中间体具有如下的结构式5:
Figure FDA0000458287090000012
其中,R1为叔丁基二甲基硅基;R为乙基。
2.一种合成如权利要求1所述的埃坡霉素碳1—6片段1的中间体的方法,其通过如下步骤(1)~(2)获得:
(1).在有机溶剂中和强碱中,化合物3和三氟甲磺酰化试剂反应0.1~2小时得到相应化合物4;所述的化合物3、三氟甲磺酰化试剂和强碱的摩尔比为1:1~5:1~5;所述的强碱是六甲基二硅氨基钾、六甲基二硅氨基钠、六甲基二硅氨基锂或二异丙基氨基锂;所述的三氟甲酰化试剂是三氟甲磺酸酐、Hendrickson试剂或Comins试剂;
(2).在有机溶剂中和催化剂存在下,化合物4与金属试剂R-M进行偶联反应0.5~10小时得到化合物5,所述的化合物4与金属试剂R-M的摩尔比为1:1~3;所述的化合物4与催化剂的摩尔比为1:0.001~0.2;所述的催化剂为Pd(PPh3)4
所述的化合物3、化合物4和化合物5分别具有如下的结构式:
Figure FDA0000458287090000013
其中,R1如权利要求1所述;所述的X为三氟甲磺酸酯;所述的R为乙基;M为Li。
3.一种如权利要求1所述的合成埃坡霉素碳1—6片段1的中间体的用途,其特征是用于合成埃坡霉素碳1—6片段1以及最终合成埃坡霉素。
CN201110158837.5A 2011-06-14 2011-06-14 合成埃坡霉素碳1-6片段的中间体、合成方法和用途 Expired - Fee Related CN102268031B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110158837.5A CN102268031B (zh) 2011-06-14 2011-06-14 合成埃坡霉素碳1-6片段的中间体、合成方法和用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110158837.5A CN102268031B (zh) 2011-06-14 2011-06-14 合成埃坡霉素碳1-6片段的中间体、合成方法和用途

Publications (2)

Publication Number Publication Date
CN102268031A CN102268031A (zh) 2011-12-07
CN102268031B true CN102268031B (zh) 2014-04-09

Family

ID=45050508

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110158837.5A Expired - Fee Related CN102268031B (zh) 2011-06-14 2011-06-14 合成埃坡霉素碳1-6片段的中间体、合成方法和用途

Country Status (1)

Country Link
CN (1) CN102268031B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675357B (zh) * 2012-01-20 2015-04-29 中国科学院上海有机化学研究所 一种合成埃坡霉素碳7-19片段的中间体、合成方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1254708A (zh) * 1999-11-12 2000-05-31 中国科学院上海有机化学研究所 埃坡霉素中间体碳1—6片段的合成新方法
US20040082651A1 (en) * 2000-10-16 2004-04-29 Wessjohann Ludger A. Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1254708A (zh) * 1999-11-12 2000-05-31 中国科学院上海有机化学研究所 埃坡霉素中间体碳1—6片段的合成新方法
US20040082651A1 (en) * 2000-10-16 2004-04-29 Wessjohann Ludger A. Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A. Fadel等,.Anhydrous ferric chloride adsorbed on silica gel induced ring enlargement of tertiary cyclobutanols : Synthesis of isolaurolene and derivatives, campholenic ether and (±) cuparene.《Tetrahedron》.1985,第41卷(第2期),第413-420页,尤其是第415页化合物13.
Anhydrous ferric chloride adsorbed on silica gel induced ring enlargement of tertiary cyclobutanols : Synthesis of isolaurolene and derivatives, campholenic ether and (±) cuparene;A. Fadel等,;《Tetrahedron》;19851231;第41卷(第2期);第413-420页,尤其是第415页化合物13 *
Carbanionic Rearrangements of (Halomethy1ene)cycloalkanes;Steve P. Samuel等,;《J. Am. Chem. Soc.》;19891231;第111卷(第4期);第1429-1436页,尤其是第1433页 *
Intramolecular Michael Addition of N- and O-Centred Nucleophiles to Tethered Acrylates. The Role of Double-Bond Geometry in Controlling the Diastereoselectivity of Cyclizations Leading to 2,6-Disubstituted Tetrahydropyrans and Piperidines;Martin G. Banwell等,;《Australian Journal of Chemistry》;19981231;第51卷;第9-18页,尤其是第10页方案2 *
MartinG.Banwell等 .Intramolecular Michael Addition of N- and O-Centred Nucleophiles to Tethered Acrylates. The Role of Double-Bond Geometry in Controlling the Diastereoselectivity of Cyclizations Leading to 2
Spiroacetals from Dienones and Hydroxyenones by Mercury(II) Cyclisation;William Kitching等,;《J. CHEM. SOC., CHEM. COMMUN.》;19861231;第855-856页 *
Steve P. Samuel等,.Carbanionic Rearrangements of (Halomethy1ene)cycloalkanes.《J. Am. Chem. Soc.》.1989,第111卷(第4期),第1429-1436页,尤其是第1433页.
William Kitching等,.Spiroacetals from Dienones and Hydroxyenones by Mercury(II) Cyclisation.《J. CHEM. SOC., CHEM. COMMUN.》.1986,第855-856页.
新型抗肿瘤药物埃坡霉素的研究;王进欣等,;《药学进展》;20040830;第28卷(第8期);第354-361页 *
王进欣等,.新型抗肿瘤药物埃坡霉素的研究.《药学进展》.2004,第28卷(第8期),第354-361页.

Also Published As

Publication number Publication date
CN102268031A (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
Howell et al. Catalytic asymmetric synthesis of acyclic arrays by tandem 1, 4-addition-aldol reactions
Chen et al. Highly stereoselective synthesis of anti, anti-dipropionate stereotriads: a solution to the long-standing problem of challenging mismatched double asymmetric crotylboration reactions
Smith et al. Total syntheses of (+)-acutiphycin and (+)-trans-20, 21-didehydroacutiphycin
CZ20032610A3 (en) Enantioselective synthesis of azetidinone intermediate compounds
Deng et al. Evolution of anion relay chemistry: construction of architecturally complex natural products
Denmark et al. Cross-coupling of vinylpolysiloxanes with aryl iodides
CN101088994A (zh) 一种紫杉醇和多西紫杉醇的合成方法
Williams et al. Synthetic Studies toward Phorboxazole A. Stereoselective Synthesis of the C28− C46 Side Chain Fragment
Marshall et al. Progress toward the Total Synthesis of Bafilomycin A1: Stereoselective Synthesis of the C15− C25 Subunit by Additions of Nonracemic Allenylzinc Reagents to Aldehydes
CN102268031B (zh) 合成埃坡霉素碳1-6片段的中间体、合成方法和用途
Crimmins et al. An aldol approach to the synthesis of the EF fragment of spongistatin 1
Hara et al. Enantioselective total synthesis of (+)-taxusin
CN101935309A (zh) 依泽替米贝的制备方法及其中间体
Junker et al. Synthesis of 4-Aryl-and 4-Alkyl-2-silyl-1, 3-butadienes and Their Diels− Alder/Cross-Coupling Reactions
Felzmann et al. Crotylation versus propargylation: two routes for the synthesis of the C13− C18 fragment of the antibiotic branimycin
White et al. Studies on the Synthesis of (−)-Gymnodimine. Subunit Synthesis and Coupling
Kwon et al. Highly regioselective cleavages and iodinations of cyclic ethers utilizing SmI2
Melillo et al. An Effective Bifunctional Aldehyde Linchpin for Type II Anion Relay Chemistry: Development and Application to the Synthesis of a C16–C29 Fragment of Rhizopodin
Marshall et al. A formal synthesis of the callipeltoside aglycone
Hunt et al. Oxabicyclo [3.2. 1] octenes in Organic Synthesis: Direct Ring Opening of Oxabicyclo [3.2. 1] Ring Systems with Diisobutylaluminum Hydride and a Silyl Ketene Acetal Synthesis of the Chiral C (19)− C (26) and C (27)− C (32) Fragments of Scytophycin C
Mochirian et al. A Bidirectional Approach to the Synthesis of Polypropionates: Synthesis of C1–C13 Fragment of Zincophorin and Related Isomers
Peters et al. Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substrates
Georg et al. The chemistry of the taxane diterpene: Stereoselective reductions of taxanes
Lakshmi et al. Synthesis of Aryl Stannanes from Silyl Triflates via Aryne Intermediates
CN101128448A (zh) 制备紫杉醇的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140409

Termination date: 20190614